Evidence map›Paper›PMID 40862945›Full record

ReviewBiosensors2025

Organic Afterglow Materials for Tumor Diagnosis and Therapy.

Xiayi Chen, Bin Li, Baoli Yin, Dong Xu, Youjuan Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiayi ChenThe Key Laboratory of Zhejiang Province for Basic and Clinical Application of Functional Nucleic Acids, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou 310022, China.ORCID 0009-0007-0732-623X
Bin LiThe Key Laboratory of Zhejiang Province for Basic and Clinical Application of Functional Nucleic Acids, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Baoli YinState Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, China.
Dong XuThe Key Laboratory of Zhejiang Province for Basic and Clinical Application of Functional Nucleic Acids, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou 310022, China.ORCID 0000-0002-0583-240X
Youjuan WangThe Key Laboratory of Zhejiang Province for Basic and Clinical Application of Functional Nucleic Acids, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou 310022, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Organic afterglow nanoparticles (OANs) represent a unique class of optical materials capable of sustaining luminescence after excitation cessation. Owing to their exceptional design flexibility, tunable optical properties, and favorable biosafety profiles, OAN-based afterglow imaging has emerged as an advanced modality in tumor diagnosis and therapy. These nanostructures demonstrate significant potential in guiding precision surgical interventions and real-time monitoring of tumor treatment, including photodynamic therapy, photothermal therapy, and immunotherapy. This review systematically analyzes and discusses the luminescence mechanisms of OANs under various excitation sources, with particular emphasis on recent developments in tumor detection and treatment. Additionally, we also discuss the current challenges and future perspectives of using these nanoparticles in this field.

Indexed as

NanoparticlesNeoplasmsOrganic ChemicalsAnimalsHumansImmunotherapyPhotochemotherapySemiconductorsUltrasonographyOrganic Chemicalsafterglow luminescence imagingorganic afterglow nanoparticlestumor diagnosis and therapy

Identifiers

PMID40862945
PMCPMC12384065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.